

SPC4061

| | |
|-----------|---|
| Cat. No.: | HY-148689 |
| CAS No.: | 1018108-22-9 |
| Target: | Ser/Thr Protease |
| Pathway: | Metabolic Enzyme/Protease |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

SPC4061

BIOLOGICAL ACTIVITY

| | |
|--------------------|---|
| Description | SPC4061 an antisense nucleotide, is a potent PCSK9 inhibitor. SPC4061 targets the lock-in nucleic acid (LNA) of PCSK9 for the study of hypercholesterolemia and related diseases ^{[1][2]} . |
| In Vitro | SPC4061 reduces PCSK9 mRNA levels in treated cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| In Vivo | SPC4061 (20 mg/kg first s.c.; and 5 mg/kg at day 7-28, once weekly for 4 weeks) produces a significant reduction in serum PCSK9 protein levels in monkey models ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

[1]. Li Chuan-Yuan, et al. PCSK9 inhibitor compositions and methods for the treatment of cancer associated with PCSK9 expression: World Intellectual Property Organization, WO2020005869 A2 2020-01-02.

[2]. Lindholm MW, et al. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther. 2012 Feb;20(2):376-81.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA